A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature

Oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene account for 5% of non-small cell lung cancer (NSCLC) cases. ALK inhibitors have markedly improved the outcome of metastatic ALK-positive NSCLC (ALK(+) mNSCLC) by increasing long-term overall survival. Although a diagnosis of NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: De Smedt, Fabian, Dessy, Frédérique, Carestia, Luciano, Baldin, Pamela, Nana, Frank Aboubakar, Clapuyt, Philippe, Boon, Véronique, Amant, Frédéric, Mhallem Gziri, Mina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827466/
https://www.ncbi.nlm.nih.gov/pubmed/36644155
http://dx.doi.org/10.3892/ol.2022.13640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827466/
https://www.ncbi.nlm.nih.gov/pubmed/36644155
http://dx.doi.org/10.3892/ol.2022.13640

Ejemplares similares